Dr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer.
Dr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer.
